Biofrontera AG

Announcement of adjustment of the option price of warrants - Seite 2

Ends

Enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer [phone] [e-mail]

IR Germany: Brainwell Asset Solutions Jürgen Benker [phone] IR UK: Seton Services Toni Vallen [phone] IR and PR US: The Ruth Group IR: Lee Roth / Tram Bui PR: Kirsten Thomas [phone] / 7035 [phone]

About Biofrontera

Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.



(end)

emitter: Biofrontera AG address: Hemmelrather Weg 201, 51377 Leverkusen country: Germany contact person: Investor & public relations phone: [phone] e-mail: [e-mail] website: www.biofrontera.com

ISIN(s): DE0006046113 (share) stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin

[ source: http://www.pressetext.com/news/20160428033 ]